

**ASX ANNOUNCEMENT**

ASX:RSH OTCQB:RSHUF

16 December 2022

**RESPIRI SECURES ADDITIONAL PRIMARY CARE SPECIALTY PRACTICE IN NEW MEXICO, USA, GENERATING REVENUES FROM DEVICE SALES AND REMOTE PATIENT MONITORING FEES****Highlights:**

- wheezo® and Access Telehealth Remote Patient Monitoring (RPM) program selected by a primary care practice in New Mexico, USA.
- Onboarding of practice completed with first patients expected to join program imminently.
- RPM Current Procedural Terminology (CPT) reimbursement claims generating revenues to Respiri to be processed within 2 months of new patients commencing the program.

**Respiri Limited (ASX:RSH, OTCQB:RSHUF) (“Respiri” or the “Company”)**, an eHealth SaaS Company supporting respiratory health management is pleased to announce it has secured a further primary care practice, Hand Family Healthcare, located in Clovis, New Mexico. The wheezo® RPM program will be provided to patients with asthma and Chronic Obstructive Pulmonary Disease (COPD). New Mexico has a large rural population making RPM an important clinical primary service given the distances patients would need to travel to receive treatment. The wheezo® device ease of use, secure integrated systems and Access Telehealth’s best in class clinical staff monitoring provides an ideal solution for such family practices.

Respiri’s RPM partner Access Telehealth will provide a full RPM solution that includes the Remotli platform, patient engagement and remote monitoring to these patients under the supervision of the Hand Family Healthcare clinical team. Hand Family Healthcare provides full-service medical services dedicated to forming strong and long-lasting relationships and utilizing leading technologies for managing their patients’ health needs.

Respiri has now secured healthcare customers located in six different states in the USA that treat and manage diverse patient groups, including both adult and pediatric patients living with asthma, patients living with COPD, patients living with COPD with underlying cardiovascular disease and primary care patients demonstrating the broad clinical appeal of the wheezo® RPM program.

Marjan Mikel, CEO of Respiri said, “Our expanding wheezo RPM footprint is further testament to the growing level of acceptance by US healthcare practitioners. The momentum we have and continue to build is an exciting growth story for the Company and with a strong and growing business development pipeline, nurtured in partnership with our RPM partners, we are confident of securing further primary healthcare practices and hospitals.”

**Approved for release by the Board of Respiri Limited**

## ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

---

### About Respiri Limited

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is an international e-Health SaaS company supporting respiratory health management focusing primarily on supporting the US remote patient monitoring market. Its world-first technology detects wheeze, a typical symptom of Asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri created technology optimises how patients in partnership with their physicians manage chronic respiratory conditions. These solutions can help transform the way physicians interact with respiratory patients while they are away from the clinic. wheezo®, is an FDA cleared Class II Medical Device, the respiri™ app (patient-user-interface) and the secure health portal can help different health organisations and providers connect with patients to improve collaboration and help improve respiratory condition management. In the USA, wheezo® can be integrated into Remote Patient Monitoring (RPM) programs and qualifies for RPM Current Procedural Terminology (CPT) reimbursement.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world with respiratory disorders and dramatically reduce hospital admissions and the economic burden of Asthma and COPD. Respiri Limited's operations are based in Melbourne, Australia with offices in New York City, USA.

For additional information about Respiri Limited please visit our corporate website [www.respiri.co/au](http://www.respiri.co/au)

### About wheezo®

Developed in Australia, with the support of an international panel leading respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the intuitive mobile application engages patients to log symptoms and triggers to build a personal profile to share data with healthcare providers so patients and physicians can have more informed discussions in relation to symptoms. The platform has been designed to extend care beyond the clinic which may lead to better health outcomes and improved quality of life for patients.

For information about our product offering in the US including wheezo® please visit [www.respiri.co/us](http://www.respiri.co/us)

wheezo® is a registered trademark of Respiri Limited.

### About Access Telehealth

Access Telehealth is a digital health company dedicated to delivering innovative connected care solutions for management of people living with chronic disease. The Remotli platform uniquely simplifies remote care delivery with patient engagement and productivity driven dashboard tools to support effective patient care and compliance. Automated care-time tracking, and reimbursement reports makes it easy to boost revenue to support vital chronic disease management programs including Remote Physiologic Monitoring, Remote Therapeutic Monitoring, Transitional Care, Chronic Care Management, Telemedicine and more. Focusing on Remote Physiologic Monitoring and virtual care initiatives, the Access Telehealth clinical team delivers patient-centric remote monitoring services to support disease specific chronic care programs for health systems, payors, and providers, to enhance care delivery. [www.accessrpm.com/](http://www.accessrpm.com/)

### Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.